Addison’s Disease Market Players, Trends Analysis, Growth Estimation By 2030

Comments · 365 Views

The Global Addison’s Disease Market Syndrome Over the forecast period, the market is predicted to increase considerably. The market is expected to be worth USD 587.45 million in 2030, and it is expected to increase at a CAGR of 10.70% over the forecast period.

Addison’s Disease Treatment Market Highlights

The increasing prevalence of Addison’s disease and rising research & development activities to produce new products for diagnosing and treating diseases is expected to drive market growth over the forecast period. According to a report published by the National Centre for Biotechnology Information in June 2017, the incidence rate of Addison’s disease is 0.6 per 100,000 of the population per year. Despite the drivers, difficulty in diagnosis in early stages and lack of knowledge can restrain the market growth over the assessment period.

Addison’s Disease Market Overview and Analysis by diagnosis, treatment, end - forecast till 2030. The Global Addison’s Disease Market is anticipated to hold a market value of USD 587.45 million in the year 2030 and is expected to grow at a CAGR of 10.70% during the forecast period. Addison’s disease occurs when the body starts producing inadequate amounts of certain hormones produced by adrenal glands. The glands start to produce too less cortisol and aldosterone as well.  Addison’s disease is a rare disorder, and only 1 in 100,000 people suffer from it.

Addison’s Disease Treatment Market Players

The global Addison’s Disease Market players are Pfizer Inc., Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, Lupin Pharmaceuticals, Inc., Abbott, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life science Pvt. Ltd., and others.


The global world market Addison has been segmented into diagnosis, treatment, and end user.

The market, based on diagnosis, has been segmented into clinical laboratory test and imaging tests. Laboratory testing is further segmented into blood tests, ACTH stimulation test, insulin-induced hypoglycaemia test, and other tests. Imaging tests are further segmented into chest radiography and CT scan.

The global market, on the basis of treatment, has been segmented into oral corticosteroids and corticosteroid injections. Oral corticosteroids are expected to hold the largest share owing to high preferability of oral dosage forms like tablets. Corticosteroid injections are anticipated to be the fastest growing segment owing to the less time required for diffusing in the bloodstream through this mode.

The global Addison’s disease market, by end user, has been segmented into hospitals and clinics, diagnostic laboratories, and other end users.

Regional Analysis

Geographically, the Americas is expected to dominate the global market owing to the presence of well-developed healthcare sector, raising awareness of the disease and favourable reimbursement policies. Europe is expected to hold the second largest position in the global market owing to the growing awareness about the disease coupled with increasing healthcare expenditure. Asia-Pacific is expected to be the fastest growing market owing to the rising prevalence of the rare disease marketing and increasing developments in pharmaceuticals & diagnostics segment. Furthermore, the Middle East and Africa region are expected to account for the least market share in the global market.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071